Abstract: The present invention provides pharmaceutical compositions, essentially comprising less than about 95% by weight of an aliphatic amine polymer. The present invention relates to pharmaceutical compositions comprising aliphatic amine polymers of sevelamer hydrochloride, sevelamer carbonate and colesevelam hydrochloride; and methods of preparing pharmaceutical compositions thereof.

Abstract: The present invention discloses a novel azelaic acid topical pharmaceutical gel composition that does not contain lecithin and a process for its preparation.

Abstract: The present invention relates generally to formulations containing raloxifene or pharmaceutical salts thereof, as the active pharmaceutical ingredient and a process for preparing the same.

Abstract: A strontium salt of esomeprazole is provided. A process for preparing a strontium salt of esomeprazole is also provided comprising reacting esomeprazole free base or a sodium, potassium or lithium salt of esomeprazole with a strontium source in one or more solvents.

Abstract: The present invention provides a composition, comprising fluocinonide in a vehicle comprising one or two penetration enhancers, solvents and emulsifiers wherein penetration enhancers are present in ratio of less than 0.90 to the total of the penetration enhancers, solvents and emulsifiers.

Abstract: The present invention generally relates to a stable pharmaceutical composition that does not have a film coating which contains simvastatin, ezetimibe or pharmaceutically-acceptable salts thereof, and ascorbic acid.

Abstract: The present invention generally relates to a a topical composition, such as a dermatological cream, containing the corticosteroid compound hydrocortisone butyrate.

Abstract: The present invention generally relates to a pharmaceutical composition. More particularly, the present invention relates to a stable topical lotion comprising at least a therapeutically effective amount of an androstane steroid compound or a pharmaceutically acceptable salt or ester thereof and one or more occlusive agents.

Abstract: A process for preparing 5H-dibenz[b,f]azepine-5-carboxamide of the general formula: wherein R1, R2, R3 and R4 are the same or different and can be hydrogen, halogen, nitro, cyano, carboxyl, R, —CO(R), —OCO(R), —O(R), —N(R)2, —CON(R)2, and —COO(R), wherein R is selected from the group consisting of C1-C10 alkyl, C3-C10 cycloalkyl, C2-C10 alkenyl, C5-C10 cycloalkenyl, C2-C10 alkynyl, and C6-C20 aryl, wherein the two A groups of —N(A)2 and —CON(A)2 can be the same or different, and wherein R2 and R3 can together form a bond is provided; the process comprising reacting 5H-dibenz[b,f]azepine of the general formula wherein R1, R2, R3 and R4 have the aforementioned meanings, with one or more alkali or alkaline-earth cyanates and in the presence of one or more unsaturated dicarboxylic acids.